Abstract
Monoclonal antibodies are established treatment options in cancer therapy. However, not all patients benefit from antibody therapy. Basic research and findings from clinical trials revealed that certain Fc-mediated effector mechanisms triggered by monoclonal antibodies are essential for efficient antitumor activity. Today, next-generation monoclonal antibodies can be designed displaying tailor-made improved effector functions. The introduction of Fc-engineering technologies offers the potential to fine-tune Fc-mediated effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC), phagocytosis, or complement-dependent cytotoxicity (CDC). Fc-engineered antibodies hopefully will overcome some limitations of current forms of antibody therapy.
Originalsprache | Englisch |
---|---|
Titel | Antibody Engineering |
Redakteure/-innen | Damien Nevoltris, Patrick Chames |
Seitenumfang | 17 |
Band | 1827 |
Erscheinungsort | New York, NY |
Herausgeber (Verlag) | Humana Press Inc. |
Erscheinungsdatum | 09.09.2018 |
Seiten | 381-397 |
ISBN (Print) | 978-1-4939-8647-7 |
ISBN (elektronisch) | 978-1-4939-8648-4 |
DOIs | |
Publikationsstatus | Veröffentlicht - 09.09.2018 |
Strategische Forschungsbereiche und Zentren
- Forschungsschwerpunkt: Gehirn, Hormone, Verhalten - Center for Brain, Behavior and Metabolism (CBBM)